The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan

Chan, Yi‐Hsin; Yeh, Yung‐Hsin; Hsieh, Mei-Yun; Chang, Chia‐Yu; Tu, Hui‐Tzu; Chang, Shang‐Hung; See, Lai‐Chu; Kuo, Chang‐Fu; Kuo, Chi‐Tai

doi:10.1016/j.ijcard.2018.02.075

Cited by 40 publications

(71 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A nationwide observational study form Taiwan found that all NOACs were associated with a lower risk of acute kidney injury compared to warfarin. 90) An analysis of a large U.S. administrative database suggested that NOACs, particularly dabigatran and rivaroxaban, may be associated with lower risks of adverse renal outcomes than warfarin. 91) …”

Section: Anticoagulation-related Nephropathymentioning

confidence: 99%

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges

et al. 2018

View full text Add to dashboard Cite

The burden of atrial fibrillation (AF) is projected to increase substantially over the next decade in parallel with the aging of the population. The increasing age, level of comorbidity, and polypharmacy will complicate the treatment of older adults with AF. For instance, advanced age and chronic kidney disease have been shown to increase the risk of both thromboembolism and bleeding in patients with AF. Frailty, recurrent falls and polypharmacy, while very common among elderly patients with AF, are often overlooked in the clinical decision making despite their significant interaction with oral anticoagulant (OAC) and profound impact on the patient's clinical outcomes. Such factors should be recognized, evaluated and considered in a comprehensive decision-making process. The introduction of non-vitamin K oral anticoagulants has radically changed the management of AF allowing for a more individualized selection of OAC. An understanding of the available data regarding the performance of each of the available OAC in a variety of at risk patient populations is paramount for the safe and effective management of this patient population. The aim of this review is to appraise the current evidence, point out the gaps in knowledge, and provide recommendations regarding stroke prevention in older adults with AF and comorbid conditions.

show abstract

Section: Anticoagulation-related Nephropathymentioning

confidence: 99%

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges

et al. 2018

View full text Add to dashboard Cite

show abstract

“…При анализе трех ПОАК по отдельности улучшение почечного прогноза было выявлено при применении ривароксабана и дабигатрана, но не апиксабана. Сходные данные были получены в очень крупном тайваньском исследовании, в которое были включены 14699 пациентов с ХБП и 60522 больных без ХБП, которым проводилась терапия различными ПОАК или варфарином в связи с наличием неклапанной ФП [52]. Лечением ривароксабаном, дабигатраном или апиксабаном по сравнению с варфарином сопровождалось достоверным снижением риска развития ОПП как у больных без ХБП (на 27-35%), так и у пациентов с ХБП (на 46-50%).…”

Section: эффективность и безопасность поак у пациентов с фп и диабетиunclassified

Prevention of cardiovascular outcomes in diabetic patients with atrial fibrillation: direct oral anticoagulants or warfarin?

2019

CPT

View full text Add to dashboard Cite

“…However, since the introduction of DOACs in clinical practice, some authors have highlighted the risk of renal dysfunction associated with the use of DOACs [2][3][4][5][6][7][8][9][10]. Warfarin has also been associated with acute and chronic renal failure (often in the setting of overanticoagulation, i.e.…”

Section: Introductionmentioning

confidence: 99%

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Marcelino

Hemett

Descombes

2020

Case Reports in Nephrology

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the prescription of rivaroxaban for atrial fibrillation, was hospitalized for a drug-induced hypersensitivity syndrome whose main clinical manifestations were low-grade fever with a petechial rash in the legs and acute renal failure (ARF). Within one week after rivaroxaban withdrawal, the patient’s clinical condition improved and the renal function normalized. In a review of the literature, we only found five case reports of rivaroxaban-related ARF: two patients had tubulo-interstitial nephritis (TIN), two had anticoagulant-related nephropathy (ARN), and the last one had IgA nephropathy. As some recent publications suggest that kidney injury due to anticoagulation drugs may be largely underdiagnosed, we also analyzed the data from the VigiAccess database, the World Health Organization pharmacovigilance program that collects drug-related adverse events from 134 national registries worldwide. Among all the rivaroxaban-associated adverse events reported in VigiAccess since 2006, 4,323 (3.5%) were renal side effects, of which 2,351 (54.3%) were due to unspecified ARF, 363 (8.4%) were due to renal hemorrhage (characteristically associated with ARN), and 24 (0.6%) were due to TIN. We also compared these results with those reported in VigiAccess for other DOACs and vitamin K antagonists. This analysis suggests that the frequency of renal adverse events associated with rivaroxaban and other DOACs may be appreciably higher than what one might currently consider based only on the small number of fully published cases.

show abstract

The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan

Cited by 40 publications

References 27 publications

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges

Prevention of cardiovascular outcomes in diabetic patients with atrial fibrillation: direct oral anticoagulants or warfarin?

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Contact Info

Product

Resources

About